US OptionsDetailed Quotes
VTYX240719C1500
- 1.05
- -0.55-34.38%
15min DelayClose Jul 19 15:59 ET
1.05High1.05Low
1.05Open1.60Pre Close1 Volume40 Open Interest1.50Strike Price105.00Turnover0.00%IV0.00%PremiumJul 19, 2024Expiry Date1.05Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.43Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Ventyx Biosciences Stock Discussion
Sign in to post a comment
$Ventyx Biosciences(VTYX.US$
Positive
▪️VTX3232 monotherapy reduced body weight and food intake in DIO mice.
▪️Significant reductions in liver triglycerides and fat deposits were observed with VTX3232.
▪️Improvements in insulin resistance and cardiometabolic parameters, including reduced cholesterol, fasting blood glucose, and HbA1c.
▪️Systemic inflammatory biomarkers (IL-1β, IL-6, fibrinogen) were reduced with VTX3232.
▪️Combination of VTX3232 and semag...
Positive
▪️VTX3232 monotherapy reduced body weight and food intake in DIO mice.
▪️Significant reductions in liver triglycerides and fat deposits were observed with VTX3232.
▪️Improvements in insulin resistance and cardiometabolic parameters, including reduced cholesterol, fasting blood glucose, and HbA1c.
▪️Systemic inflammatory biomarkers (IL-1β, IL-6, fibrinogen) were reduced with VTX3232.
▪️Combination of VTX3232 and semag...
1
1
$Ventyx Biosciences(VTYX.US$ Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant Nlrp3 Inhibitor Vtx3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers
1
$Ventyx Biosciences(VTYX.US$ $NIO Inc(NIO.US$ $Eli Lilly and Co(LLY.US$ $Structure Therapeutics(GPCR.US$
Obesity Drug - Update & Battle for Skinny
SubQ- $VKTX ph2 results puts the company in driver's seat after showing impressive results both in efficacy and safety
$VKTX has shown twice as much weight loss in 13 weeks what $LLY has done in 12 weeks and what $NVO has shown in 40 plus weeks
In safety, VKTX shown its superiority too vs LLY and NVO
For comparison...
Obesity Drug - Update & Battle for Skinny
SubQ- $VKTX ph2 results puts the company in driver's seat after showing impressive results both in efficacy and safety
$VKTX has shown twice as much weight loss in 13 weeks what $LLY has done in 12 weeks and what $NVO has shown in 40 plus weeks
In safety, VKTX shown its superiority too vs LLY and NVO
For comparison...
Morning Movers
Gapping up
$Oracle(ORCL.US$ The information technology company saw its stock climb 13.3% due to strong per-share earnings, with adjusted earnings per share of $1.41 surpassing the consensus estimate.
$Kohl's Corp(KSS.US$ The retailer's shares increased by 2.2% after reporting earnings and revenue that exceeded expectations for the fourth quarter.
$Coinbase(COIN.US$ The cryptocurrency trading platform's shares...
Gapping up
$Oracle(ORCL.US$ The information technology company saw its stock climb 13.3% due to strong per-share earnings, with adjusted earnings per share of $1.41 surpassing the consensus estimate.
$Kohl's Corp(KSS.US$ The retailer's shares increased by 2.2% after reporting earnings and revenue that exceeded expectations for the fourth quarter.
$Coinbase(COIN.US$ The cryptocurrency trading platform's shares...
25
3
$Ventyx Biosciences (VTYX.US)$ good breakout and gapfill zone at 13.5. Fda approvals in pipeline. Good to play upside momentum with stoploss 6
1
The stock market started off on a good note and really picked up speed at 10 pm (GST +8) after a very positive ISM Manufacturing report, which showed just the right balance of growth without too much inflation. On top of that, the tech sector, which was already doing well, received an extra boost from a highly praised report by DELL. By the end of the trading session, stocks closed near their highest points for the day, with more stocks reaching new highs on both maj...
15
$Ventyx Biosciences(VTYX.US$ likely to get FDA approval this week.
1
No comment yet
72839823 : Why is stock going down?